Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634791 | 1.00 | PARP1 (0.42) | PARP1NR1H2NR1H3PTPN1HSD17B10 | |
| SCHEMBL6350612 | 1.00 | PARP1 (0.42) | PARP1NR1H2NR1H3PTPN1HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL22169218 | 0.99 | PARP1 (0.42) | PARP1NR1H2NR1H3PTPN1HSD17B10 | |
| Hydrochloric Acid SCHEMBL15645732 | 0.99 | PARP1 (0.42) | PARP1NR1H2NR1H3PTPN1HSD17B10 | |
| SCHEMBL25572934 | 0.92 | HSD17B10 (0.43) | PARP1NR1H2NR1H3PTPN1HSD17B10 | |
| SCHEMBL18673224 | 0.91 | PARP1 (0.44) | PARP1NR1H2NR1H3HSD17B10SMN1; SMN2 | |
| SCHEMBL2584375 | 0.91 | PARP1 (0.44) | PARP1NR1H2NR1H3HSD17B10SMN1; SMN2 | |
| SCHEMBL28442303 | 0.88 | PARP1 (0.38) | PARP1NR1H2NR1H3HSD17B10SMN1; SMN2 | |
| SCHEMBL7995550 | 0.88 | PARP1 (0.44) | PARP1NR1H2NR1H3HSD17B10SMN1; SMN2 | |
| SCHEMBL6198122 | 0.86 | TSHR (0.40) | ITGB2ICAM1ITGALFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250282760-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12286434-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2025-04-29 | — | — | US | disclosed |
| EP-4518853-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1268449-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6458790-B2 | DIETETICS; ANTIDABETIC AGENTS; SEXUAL DISRDERS | MERCK & CO., INC. | 2002-10-01 | — | — | US | disclosed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | disclosed |
| CN-1350520-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-05-22 | — | — | CN | disclosed |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MERCK SHARP & DOHME CORP. | 2002-02-14 | — | — | US | disclosed |
| WO-2001070708-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | PARP1 176/4885NR1H2 2419/4885NR1H3 2328/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | PARP1 1612/4885NR1H2 3336/4885NR1H3 3617/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PARP1 101/4885NR1H2 2901/4885NR1H3 2749/4885 |
| US-20250282760-A1 | OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | PARP1 4754/4885NR1H2 61/4885NR1H3 79/4885 |
| US-12286434-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | PARP1 630/4885NR1H2 297/4885NR1H3 238/4885 |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MC4R, MC5R, MC3R | PARP1 1985/4885NR1H2 2191/4885NR1H3 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.